Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)’s share price fell 3.4% during mid-day trading on Wednesday . The stock traded as low as $2.14 and last traded at $2.29, with a volume of 798,291 shares trading hands. The stock had previously closed at $2.37.

Separately, Zacks Investment Research cut Aegerion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 25th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Aegerion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $13.21.

The firm has a 50-day moving average price of $1.63 and a 200-day moving average price of $2.30. The firm’s market capitalization is $68.47 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/aegerion-pharmaceuticals-inc-aegr-shares-down-3-4.html

Aegerion Pharmaceuticals (NASDAQ:AEGR) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.34. Aegerion Pharmaceuticals had a negative net margin of 80.76% and a negative return on equity of 128.77%. The business earned $44.50 million during the quarter, compared to analyst estimates of $35.50 million. Equities analysts forecast that Aegerion Pharmaceuticals Inc. will post ($3.44) earnings per share for the current fiscal year.

In other news, major shareholder Healthcare Master Fun Broadfin acquired 276,000 shares of the company’s stock in a transaction on Monday, September 12th. The shares were bought at an average price of $1.66 per share, with a total value of $458,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.60% of the company’s stock.

Several institutional investors have recently modified their holdings of AEGR. Artal Group S.A. purchased a new position in shares of Aegerion Pharmaceuticals during the second quarter valued at about $1,490,000. Eqis Capital Management Inc. raised its position in shares of Aegerion Pharmaceuticals by 3.9% in the second quarter. Eqis Capital Management Inc. now owns 87,458 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 3,255 shares during the last quarter. Squarepoint Ops LLC raised its position in shares of Aegerion Pharmaceuticals by 9.1% in the first quarter. Squarepoint Ops LLC now owns 34,906 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 2,906 shares during the last quarter. Royal Bank of Canada raised its position in shares of Aegerion Pharmaceuticals by 1,193.5% in the first quarter. Royal Bank of Canada now owns 58,247 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 53,744 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Aegerion Pharmaceuticals during the first quarter valued at about $574,000. 87.60% of the stock is currently owned by institutional investors.

Aegerion Pharmaceuticals Company Profile

Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.

5 Day Chart for NASDAQ:AEGR

Receive News & Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.